The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
Maxx Pharma Pty Ltd
Regulatory activities for this sponsor.
Loading...
Sponsor content
33 result(s) found, displaying 21 to 30
-
-
Prescription medicine registrationActive ingredients: eslicarbazepine acetate.
-
Cancellation by sponsorRequested by Maxx Pharma Pty Ltd
-
Cancellation by sponsorRequested by Maxx Pharma Pty Ltd
-
Australian Public Assessment Report (AusPAR)Australian Public Assessment Report for Opicapone
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for OGIVRI trastuzumab (rch) 150 mg powder for injection vial.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for OGIVRI trastuzumab (rch) 440 mg powder for injection vial with bacteriostatic water for injection.
-
Prescription medicine decision summaryTGA decision: Ongentys (opicapone) is approved as adjunctive therapy in adult patients with Parkinson's disease.
-
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for FULPHILA pegfilgrastim 6 mg/0.6 mL pre-filled syringe.